In 2024, the global radioimmunoassay market was valued at USD 1.51 billion, and it is projected to grow to USD 1.79 billion by 2030, representing a CAGR of 2.93 % between 2025 and 2030. The key driver behind this growth is the rising demand for highly accurate and sensitive diagnostic techniques across diverse clinical areas, where precise quantitation of biomarkers (such as hormones, drugs, and tumor markers) is critical.

Key Market Trends & Insights

• In 2024, North America held the largest share of the radioimmunoassay market, capturing 47.43 % of the global total.
• Over the forecast period, Asia Pacific is expected to be the fastest-growing region, with an estimated CAGR of 20.10 %.
• From a product standpoint, reagents and kits dominated in 2024, accounting for 73.22 % of the market.
• On the basis of application, clinical diagnostics commanded the largest revenue share that year.
• In terms of end use, hospitals were the leading segment in 2024, given their role in routine diagnostic testing and chronic disease monitoring.

Market Size & Forecast

• 2024 Market Size: USD 1.51 billion
• 2030 Projected Size: USD 1.79 billion
• CAGR (2025–2030): 2.93 %

As healthcare systems increasingly emphasize early disease detection and personalized medicine, radioimmunoassay plays a vital role in accurately measuring very low concentrations of analytes. Growth is further bolstered by increased research in endocrinology, oncology, and infectious diseases, as well as wider adoption of RIA in both developed and emerging regions.

Demographic changes, especially growth of populations with chronic conditions, stimulate the demand for more sensitive diagnostics.

The high prevalence of conditions such as thyroid disorders, cancer, HIV/AIDS, hepatitis, and cardiovascular disease reinforces the need for precision assays. For example, the global HIV–AIDS burden in 2023 was estimated at 39.9 million infected individuals, with 1.3 million new infections that year.

RIA’s high specificity and sensitivity make it particularly valuable for detecting trace-level biomarkers in complex biological media — areas where alternative immunoassays may fall short.

Technological advances, including improved radiolabeled reagents, assay automation, and safer waste handling, are reducing operational risks and boosting adoption. The increasing volume of blood donations and the need for rigorous infectious screening also support ongoing demand for RIA solutions in blood banks and diagnostic labs.

Order a free sample PDF of the Radioimmunoassay Market Intelligence Study, published by Grand View Research.

Key Companies & Market Share Insights

The radioimmunoassay industry is characterized by strong competition and technological innovation. Established players invest heavily in research and development, merging with or acquiring niche firms to broaden their portfolios and global reach. The sector faces stringent regulatory oversight due to the use of radioactive materials, which raises barriers to entry but also drives innovation in safer alternatives.

Companies are expanding product lines to include multiplex assays, disease-specific kits, and automation features. Regional expansion is ongoing, especially in Asia-Pacific, Latin America, and the Middle East, where local manufacturing, partnerships, and customised offerings help penetrate new markets.

Major players maintain competitive advantage through continual product upgrades and strategic acquisitions. Meanwhile, emerging firms focus on differentiation and collaborations with academic and governmental institutions to strengthen their presence.

These firms collectively hold considerable market share and guide technological trends in the RIA sector. In addition, players like Autobio Diagnostics Co., Ltd and Izotop are gaining traction, emphasizing innovation and partnerships to expand their influence.

Recent developments:

• In January 2025, a company extended the shelf life of certain RIA kits, adding two extra weeks of stability.
• In December 2022, a novel one-step RIA assay for thyroid-stimulating hormone receptor antibodies was launched, shortening incubation time to 120 minutes.
• In October 2022, one of the major firms acquired a multiplex diagnostics company, aiming to integrate cross-platform assay capabilities.
• A strategic agreement in 2020 saw the transfer of a radioimmunoassay portfolio between two players to preserve continuous support for critical assays, including peptide hormone quantification.

Key Companies List

Here is the roster of principal companies shaping the radioimmunoassay space:

• DIAsource
• Tecan Trading AG
• PerkinElmer
• DRG International Inc.
• Oxford BioSystems
• DiaSorin S.p.A.
• Eurodiagnóstico, S.L.
• MP Biomedicals
• Merck KGaA

Additionally, newer entrants like Autobio Diagnostics Co., Ltd and Izotop are emerging through product innovation and strategic alliances.

Conclusion

The radioimmunoassay market is poised for steady expansion, driven by increasing demand for ultra-sensitive diagnostic methods, technological innovations, and growing incidences of chronic and infectious diseases. While established firms dominate through scale, innovation, and acquisitions, emerging players are gaining momentum through niche differentiation and collaboration. Regions such as Asia Pacific offer significant growth potential, and the evolution of safer, more automated RIA solutions positions the market to support next-generation precision diagnostics.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.